IL22 and neoplasm: Because all our findings presented above are based on a DSS or AOM/DSS inflammation-associated model (a tumor prevention model), blocking immune cell infiltration through TH17 cells or their cytokines (IL-17 and/or IL-22) markedly reduces inflammation-induced colitis and tumor development.